US 12,201,558 B2
Apparatus and methods for ocular injection
Rafael Victor Andino, Grayson, GA (US); Vladimir Zarnitsyn, Atlanta, GA (US); Jesse Yoo, Snellville, GA (US); Christopher John Brooks, Glen Cove, NY (US); Trent John Kahute, Atlanta, GA (US); Justin William Arsenault, Atlanta, GA (US); David Jackson Trettin, Atlanta, GA (US); Andrew Kent Bauer, Atlanta, GA (US); and Stephanie Elaine Lewis, Atlanta, GA (US)
Assigned to Clearside Biomedical, Inc., Alpharetta, GA (US)
Filed by CLEARSIDE BIOMEDICAL, INC., Alpharetta, GA (US)
Filed on Jan. 19, 2023, as Appl. No. 18/156,684.
Application 18/156,684 is a continuation of application No. 16/510,238, filed on Jul. 12, 2019, granted, now 11,559,428.
Application 16/510,238 is a continuation of application No. 16/381,213, filed on Apr. 11, 2019, granted, now 10,517,756, issued on Dec. 31, 2019.
Application 16/381,213 is a continuation of application No. 15/946,838, filed on Apr. 6, 2018, granted, now 10,555,833, issued on Feb. 11, 2020.
Application 15/946,838 is a continuation of application No. 15/714,441, filed on Sep. 25, 2017, granted, now 9,937,075, issued on Apr. 10, 2018.
Application 15/714,441 is a continuation of application No. 15/472,551, filed on Mar. 29, 2017, granted, now 9,770,361, issued on Sep. 26, 2017.
Application 15/472,551 is a continuation of application No. 15/399,239, filed on Jan. 5, 2017, granted, now 9,636,253, issued on May 2, 2017.
Application 15/399,239 is a continuation of application No. 14/268,687, filed on May 2, 2014, granted, now 9,539,139, issued on Jan. 10, 2017.
Claims priority of provisional application 61/953,147, filed on Mar. 14, 2014.
Claims priority of provisional application 61/944,214, filed on Feb. 25, 2014.
Claims priority of provisional application 61/827,371, filed on May 24, 2013.
Claims priority of provisional application 61/819,052, filed on May 3, 2013.
Claims priority of provisional application 61/819,048, filed on May 3, 2013.
Prior Publication US 2023/0157869 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 9/00 (2006.01); A61J 1/20 (2006.01); A61M 5/20 (2006.01); A61M 5/31 (2006.01); A61M 5/32 (2006.01); A61M 5/34 (2006.01); A61M 5/46 (2006.01); A61M 5/48 (2006.01); A61M 37/00 (2006.01); A61M 5/315 (2006.01)
CPC A61F 9/0017 (2013.01) [A61J 1/201 (2015.05); A61J 1/2055 (2015.05); A61J 1/2096 (2013.01); A61M 5/2033 (2013.01); A61M 5/2053 (2013.01); A61M 5/31 (2013.01); A61M 5/3293 (2013.01); A61M 5/34 (2013.01); A61M 5/344 (2013.01); A61M 5/346 (2013.01); A61M 5/347 (2013.01); A61M 5/348 (2013.01); A61M 5/349 (2013.01); A61M 5/46 (2013.01); A61M 5/482 (2013.01); A61M 37/0015 (2013.01); A61F 2250/0007 (2013.01); A61F 2250/0069 (2013.01); A61M 2005/31508 (2013.01); A61M 2037/0023 (2013.01); A61M 2037/0061 (2013.01); A61M 2210/0612 (2013.01)] 27 Claims
OG exemplary drawing
 
1. An apparatus, comprising:
a medicament container, the medicament container including an adeno-associated virus (AAV);
a housing configured to receive a portion of the medicament container;
a hub configured to be coupled to the medicament container and defining a passageway through which a puncture member is disposed, the hub being fixedly coupled to the puncture member such that the hub moves with the puncture member when the puncture member is moved relative to an eye, a distal end surface of the hub being configured to contact a target surface of the eye when the AAV is conveyed through the puncture member; and
an actuation rod at least partially disposed within the medicament container, the medicament container, the actuation rod, and the puncture member collectively configured such that (1) a portion of the actuation rod moves within the medicament container in response to a manually-applied force on the actuation rod when a distal end portion of the puncture member is disposed within a suprachoroidal space of the eye, and (2) movement of a distal end portion of the actuation rod within the medicament container in response to the force on the actuation rod is limited when the distal end portion of the puncture member is disposed within a portion of a sclera of the eye, the force having a magnitude less than a threshold value.